Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 4,875 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 4,875 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $22.72, for a total value of $110,760.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Anish Patel also recently made the following trade(s):

• On Thursday, April 11th, Anish Patel sold 17,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.03, for a total value of $438,025.00.
• On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.60, for a total value of $90,675.00.
• On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.64, for a total transaction of $76,245.00.

Enliven Therapeutics Trading Down 0.9 %

Enliven Therapeutics stock traded down $0.21 during trading hours on Wednesday, reaching $24.49. 432,449 shares of the stock were exchanged, compared to its average volume of 246,453. The stock has a 50 day moving average of $17.82 and a two-hundred day moving average of $14.96. The company has a market cap of $1.15 billion, a P/E ratio of -11.18 and a beta of 1.05. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, analysts expect that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective on the stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its position in Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after purchasing an additional 1,029 shares during the period. SG Americas Securities LLC grew its holdings in shares of Enliven Therapeutics by 17.8% in the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after acquiring an additional 2,041 shares in the last quarter. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics during the 4th quarter valued at $28,000. Exchange Traded Concepts LLC increased its holdings in Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after buying an additional 2,208 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 67.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.